SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2022 Financial Results
– Cash Position of $21.3 Million as of September 30, 2022 – – Hosting Phase 3 REGAL Study Update Webcast...
Day: November 14, 2022
Virbac : Declaration of the number of shares and voting rights 10/2022
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information...
Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction
Company will focus on its high growth, high margin pediatric and rare disease business, powered by whole exome/genome diagnostic testing...
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
- SHINE Alzheimer’s Trial Expands to European Sites - - SEQUEL Alzheimer’s Trial Awarded Additional NIA Grant to Complete -...
Immutep Receives Australian R&D Tax Incentive
Media Release (Code: ASX: IMM; NASDAQ: IMMP) SYDNEY, AUSTRALIA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ:...
ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Continued execution to advance exebacase and CF-370 into new clinical studiesYONKERS, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation...
Revolo Biotherapeutics to Present at TIDES Europe 2022
NEW ORLEANS and LONDON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies...
MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs
Financing led by Wellington Management with participation from other leading healthcare fundsCARMEL, Ind., Nov. 14, 2022 (GLOBE NEWSWIRE) -- MBX...
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update
NORCROSS, Ga., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results
-- Achieved key clinical and regulatory milestones across clinical pipeline, including the completion of enrollment in Longeveron’s Phase 2a trial...
Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting
SALT LAKE CITY, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and...
MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update
MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update Global trial of sonelokimab in Hidradenitis Suppurativa...
IMUNON Reports Third Quarter 2022 Financial Results and Provides Business Update
Conference Call Today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a...
Universe Pharmaceuticals INC Regains Compliance with Nasdaq Minimum Bid Price Requirement
Ji’an, Jiangxi, China, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and...
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Paltusotine’s Phase 3 PATHFNDR-1 trial in acromegaly fully enrolled and on track for topline data in Q3 2023 Paltusotine lowered...
Important Reminder for Eargo Stockholders of Record as of October 24, 2022
DEADLINE TO PARTICIPATE IN EARGO RIGHTS OFFERING FOR U.S. HOLDERS WHO HOLD SHARES THROUGH A BROKERAGE ACCOUNT:2:15 P.M., NEW YORK...
iCAD to Present at HLTH 2022 With Google
Google invites iCAD’s President and CEO, Stacey Stevens, to be a featured speaker in the Google Health Theater Room on...
Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334
Healthy volunteer study will inform development of 4334 for treatment of hepatitis B virus SOUTH SAN FRANCISCO, Calif., Nov. 14,...
Impel Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Corporate Update
Trudhesa® nTRx Increased by 27% in Q3 2022 vs. Q2 2022 to 16.7k: Net Product Revenue Increased to $3.1 Million...
Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study
DARE-VVA1 Demonstrated Improvement in Vaginal Cytology Parameters and Bothersome Symptoms of Vulvar and Vaginal Atrophy (VVA), Supporting Ongoing Development Investigational...